Karyopharm Therapeutics (KPTI) PT Lowered to $6 at Wedbush
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/24/2024
- Wall Street closes higher as investors digest earnings, megacap outlook
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil rises as dollar slips, focus shifts to economic data
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Wolfe Research Downgrades Warner Brothers Discovery (WBD) to Underperform, 'out of concern that an incipient advertising downturn put guidance at risk'
- Wall Street closes higher as investors digest earnings, megacap outlook
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
Karyopharm Therapeutics (KPTI) PT Lowered to $16 at RBC Capital
March 1, 2019 6:49 AM ESTRBC Capital analyst Brian Abrahams lowered the price target on Karyopharm Therapeutics (NASDAQ: KPTI) to $16.00 (from $17.00) while maintaining a Outperform rating.
... MoreKaryopharm Therapeutics (KPTI) PT Cut To $15 At Baird As Full Approval Delayed
February 27, 2019 6:37 AM ESTBaird analyst, Michael Ulz, reiterated his Outperform rating on shares of Karyopharm Therapeutics (NASDAQ: KPTI) after he cut his price target to $15 from $25 after an ODAC panel voted against (8/5) accelerated approval of selinexor in triple class refractory multiple myeloma.
The... More
RBC Still Sees Value for Karyopharm Therapeutics' (KPTI) Selinexor Albeit Delayed, PT To $17
February 27, 2019 6:29 AM ESTRBC Capital analyst, Brian Abrahams, reiterated his Outperform rating on shares of Karyopharm Therapeutics (NASDAQ: KPTI) and cut his price target to $17.00 (from $24.00) after the FDA's ODAC panel voted 8-5 against accelerated approval of lead drug selinexor in triple-class refractory multiple myeloma (MM),... More
Karyopharm (KPTI) Confirms Panel Recommended FDA Wait for Results from Phase 3 BOSTON Study of Selinexor in Patients R/R MM before Making Final Decision on Approval
February 27, 2019 6:24 AM ESTKaryopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) met to discuss the New Drug Application (NDA) for selinexor, a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound. The NDA, which is currently under Priority Review by the FDA, is seeking accelerated approval for selinexor in combination with dexamethasone for the treatment of patients with relapsed refractory multiple myeloma who have received at least three prior therapies and whose disease is refractory to at least one proteasome inhibitor... More
BofA/Merrill Lynch Downgrades Karyopharm Therapeutics (KPTI) to Underperform
February 27, 2019 6:13 AM ESTBofA/Merrill Lynch analyst Ying Huang downgraded Karyopharm Therapeutics (NASDAQ: KPTI) from Neutral to Underperform with a price target of $5.00 (from $15.00).
For an analyst ratings summary and ratings history on Karyopharm Therapeutics click here. For more ratings news on Karyopharm Therapeutics click here.
Shares of Karyopharm Therapeutics closed at $4.20 yesterday.
... More
